Dr Ying Huang speaks to ecancer about the first-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

He explains that LB2501 is designed to generate CAR-T cells directly within the patient, eliminating the need for ex vivo manufacturing and lymphodepleting chemotherapy. The treatment is administered as a single intravenous infusion and represents a novel off-the-shelf approach to CAR-T therapy.

Dr Huang report a favourable safety profile, with no dose-limiting toxicities, serious adverse events, or neurotoxicity observed. At the higher dose level, the objective response rate was 100% and the complete response rate was 83.3%, with all responses ongoing at the time of analysis.

These early findings demonstrate the feasibility of in vivo CAR-T generation and support further development of LB2501 as a potentially more accessible cellular immunotherapy for B-cell malignancies.